01—Abstract
Summary
Summary of the 10-Q filed May 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. reported first-quarter 2025 total revenues of $264.9 milliona, up from $195.9 million in the prior-year quarter, with royalties of $168.2 million (up 39%) as the largest driver.
Product sales, net rose to $78.0 millionb, led by bulk rHuPH20 sales of $27.0 million, and revenues under collaborative agreements were $18.6 million, including a $15.0 million sales-based milestone. Operating income was $141.5 million versus $95.5 million a year earlier, and net income was $118.1 million, or $0.93 per diluted share, compared with $76.8 million, or $0.60 per diluted share. The balance sheet shows cash, cash equivalents and marketable securities of $747.9 million as of March 31, 2025, against long-term debt, net of $1.51 billion, which consists of the 2027 and 2028 convertible notes with total principal of $1.525 billion.
Net cash from operating activities was $154.2 millionc. During the quarter the company completed a $250.0 million accelerated share repurchase, retiring 4.7 million shares at $53.95 per share, and it stated that $500.0 million remained available under the February 2024 program. Management stated that current cash and marketable securities are sufficient to fund operations for at least the next 12 months.
The filing also notes subsequent developments, including the April 2025 filing of a patent infringement lawsuit against Merck Sharp & Dohme Corp. over its MDASE technology, and several partner regulatory approvals in Europe and the U.S., such as Janssen's SC RYBREVANT approval in the EU and argenx's FDA approval of a VYVGART Hytrulo prefilled syringe. The company also disclosed that its CEO, Helen Torley, adopted Rule 10b5-1 trading arrangements covering up to 628,492 shares in total.
02—Key points
Key Highlights
- Total revenues of $264.9 million, up from $195.9 million in Q1 2024; royalties rose to $168.2 million from $120.6 million (up 39%).
- Product sales, net of $78.0 million, up 33%, driven by bulk rHuPH20 sales of $27.0 million (up 157%) and device partnered product sales of $14.7 million.
- Net income of $118.1 million, or $0.93 per diluted share, versus $76.8 million, or $0.60 per diluted share, a year earlier.
- Cash, cash equivalents and marketable securities totaled $747.9 million as of March 31, 2025; the company believes this is sufficient for at least the next 12 months.
- Completed the $250.0 million accelerated share repurchase in March 2025 (4.7 million shares at $53.95); $500.0 million remained under the $750.0 million February 2024 program.
- Long-term debt, net, of $1.51 billion consists of 0.25% convertible notes due 2027 and 1.00% convertible notes due 2028, with total principal of $1.525 billion.
- Filed a patent infringement lawsuit against Merck in April 2025 alleging use of Halozyme's MDASE technology to develop SC Keytruda.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Halozyme Therapeutics kept $0.45.
- Revenue$264.9M100.0%
- Cost of revenue−$48.4M18.3%
- Gross profit$216.5M81.7%
- Operating costs−$74.9M28.3%
- Operating income$141.5M53.4%
- Interest, other & tax−$23.4M8.8%
- Net income$118.1M44.6%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 6, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $264.86M$195.88M | +35.2% |
| Cost of Revenue | $48.40M$28.33M | +70.9% |
| Gross Profit | $216.46M$167.55M | +29.2% |
| R&D Expenses | $14.80M$19.11M | −22.6% |
| SG&A Expenses | $42.36M$35.13M | +20.6% |
| Operating Expenses | $123.33M$100.34M | +22.9% |
| Operating Income | $141.53M$95.54M | +48.1% |
| Net Income | $118.09M$76.82M | +53.7% |
| EPS (Basic) | $0.96$0.61 | +57.4% |
| EPS (Diluted) | $0.93$0.60 | +55.0% |
| Shares Outstanding (Basic) | 123.22M126.94M | −2.9% |
| Shares Outstanding (Diluted) | 126.64M128.89M | −1.7% |
05—Questions
Frequently Asked Questions
What drove the growth in royalty revenue this quarter?
The filing attributes the increase in royalties primarily to continued sales uptake of VYVGART Hytrulo by argenx, DARZALEX SC by Janssen, and Phesgo by Roche across all geographies. Royalties were $168.2 million versus $120.6 million, a 39% increase.
How did the company's cash position and capital return activity change?
Cash and cash equivalents rose to $176.3 million from $115.9 million at December 31, 2024, and marketable securities rose to $571.6 million from $480.2 million. The company completed a $250.0 million accelerated share repurchase in March 2025 and retained $500.0 million of authorization under the February 2024 program.
What are the company's main debt obligations?
Halozyme has $805.0 million of 0.25% convertible senior notes due March 1, 2027 and $720.0 million of 1.00% convertible senior notes due August 15, 2028. The $250.0 million revolving credit facility portion of the 2022 facility was undrawn as of March 31, 2025, and the company stated it was in compliance with all covenants.
Did the company disclose any material legal proceedings?
The company stated it is not a party to any legal proceedings expected to have a material adverse effect. It did disclose that in April 2025 it filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in the U.S. District Court in New Jersey, seeking damages and injunctive relief over the MDASE technology.
What were the key drivers of the change in operating expenses?
Cost of sales rose to $48.4 million from $28.3 million, primarily due to higher product sales. SG&A rose to $42.4 million from $35.1 million on higher consulting, professional service and compensation expense, while research and development fell to $14.8 million from $19.1 million due to lower compensation expense and the timing of ENHANZE investments.
06—Continue